{
  "abstract": "Background and Importance The need to optimise the production of drugs used in cancer treatment, as well as reduce the length of time patients spend in hospital, led to the development of dose banding. This involves preparing batches of pre-established doses. It is important to identify the circumstances in which dose banding can achieve these goals without additional costs to the institution and the environment.Aim and Objectives Simulate the results of implementing dose banding for the preparation of anticancer drugs in a district general hospital.Material and Methods A retrospective study was conducted based on preparations made during 2023. All drugs with more than 250 preparations, which were physically and chemically stable for at least 7 days, were considered. Using the logarithmic method to establish the intervals for each band, five bands were defined to cover 60% of preparations, with differences of less than 5% from the individualised dose. The weekly stock required and the waste due to expiration were calculated.Results Four candidate drugs met the criteria: bevacizumab, irinotecan, paclitaxel and trastuzumab. Of the 557 bevacizumab preparations, 322 could be assigned to a defined band, with dose differences ranging from -3.3% to +3.3%. Of the 1,001 irinotecan preparations, 571 could use the defined bands, with dose differences ranging from -3.9% to +4.2%. Of the 1,157 paclitaxel preparations, 619 could use the defined bands, with dose differences ranging from -2.2% to +2.6%. Of the 684 trastuzumab preparations, 404 could use the defined bands, with dose differences ranging from -2.6% to +2.7%. Preparing these four substances in dose banding would result in a waste for expiration of 20 bevacizumab preparations (3.6%), 20 irinotecan (2.0%), 196 paclitaxel (16.6%), and 21 trastuzumab (3.1%).Conclusion and Relevance A simulation analysis of a dose banding system showed that the potential benefits of dose banding are accompanied by significant waste. Further analysis is required to determine the feasibility of implementing this strategy, considering the drugs involved, the number of bands and the potential gains and losses for patients and the hospital.References and/or Acknowledgements 1. Albert-Marí A, Valero-García S, Fornés-Ferrer V, et al. Exploratory analysis for the implementation of antineoplastic logarithmic dose banding. Int J Clin Pharm 2018;40:1281–1291. https://doi.org/10.1007/s11096-018-0714-9Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Unidade Local De Saúde Do Alto Ave, Pharmacy, Guimarães, Portugal"
      ],
      "name": "C Barbosa"
    },
    {
      "affiliations": [
        "Unidade Local De Saúde Do Alto Ave, Pharmacy, Guimarães, Portugal"
      ],
      "name": "A Araújo"
    },
    {
      "affiliations": [
        "Unidade Local De Saúde Do Alto Ave, Pharmacy, Guimarães, Portugal"
      ],
      "name": "AR Fortunato"
    },
    {
      "affiliations": [
        "Faculty of Pharmacy, University of Porto, Laboratory of Pharmacology, Department of Drug Sciences, Porto, Portugal"
      ],
      "name": "F Fernandez-Llimos"
    }
  ],
  "title": "3PC-023 Simulation of dose banding implementation in the preparation of anticancer drugs",
  "uid": "65ee015d-7a6d-5234-bf09-b34d758102c0"
}